Pfizer's LORBRENA CROWN Study Shows Majority Of Patients With ALK-Positive Advanced Lung Cancer Living Beyond 5-Years Without Disease Progression
Portfolio Pulse from Benzinga Newsdesk
Pfizer's Phase 3 CROWN trial shows that 60% of patients with ALK-positive advanced lung cancer treated with LORBRENA remain alive without disease progression after five years, compared to 8% with XALKORI. The study also shows an 81% reduction in the risk of progression or death and a 94% reduction in brain metastases progression with LORBRENA.
May 31, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's LORBRENA demonstrates significant long-term efficacy in treating ALK-positive advanced lung cancer, with 60% of patients remaining progression-free after five years. This could boost investor confidence and positively impact Pfizer's stock price.
The impressive results from the CROWN trial highlight LORBRENA's superior efficacy over XALKORI, which could lead to increased adoption and sales. This positive development is likely to enhance investor sentiment and drive Pfizer's stock price upward.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100